Search results
Loren David Walensky is a professor of pediatrics and a cancer researcher at Harvard Medical School and Dana Farber Cancer Institute. He develops and applies stapled peptides to block protein interactions that cause cancer and extends his work to clinical testing.
Dr. Walensky is a pediatric hematology/oncology physician and researcher at Dana-Farber and Harvard Medical School. He develops novel peptides to treat various cancers and is the director of the Harvard/MIT MD-PhD Program.
Dr. Walensky is a physician and researcher at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. He specializes in hematologic malignancies and develops novel peptide drugs to target cancer proteins.
People also ask
Who is Loren Walensky?
Who is Dr Walensky?
What does the Walensky laboratory do?
Loren David Walensky is an American physician-scientist and pediatric oncologist at the Dana–Farber Cancer Institute since 2003 and a professor of pediatrics at the Dana–Farber/Harvard Cancer Center. He researches peptides and oncogenic pathways. In 2013, Walensky became director of the joint MD/PhD program at Harvard Medical School.
- 3
- .mw-parser-output .marriage-line-margin2px{line-height:0;margin-bottom:-2px}.mw-parser-output .marriage-line-margin3px{line-height:0;margin-bottom:-3px}.mw-parser-output .marriage-display-ws{display:inline;white-space:nowrap}, Rochelle Walensky (m. 1995)
486. 2010. The challenge of drugging undruggable targets in cancer: lessons learned from targeting BCL-2 family members. GL Verdine, LD Walensky. Clinical cancer research 13 (24), 7264-7270. , 2007. 475. 2007. Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma.
May 1, 2019 · Loren David Walensky is a professor of pediatrics and a researcher in molecular pharmacology and biochemistry. He studies the regulation and inhibition of apoptosis, the role of BCL-2 family proteins in cancer and neurodegeneration, and the design of novel antimicrobial peptides.
Loren Walensky is an attending physician and researcher at Dana-Farber/Boston Children's Cancer and Blood Disorders Center. He specializes in pediatric hematology-oncology and develops novel peptide drugs for cancer treatment.
